Why OnCusp Therapeutics’ CFO hire matters for its CDH6 antibody-drug conjugate strategy
CDH6 ADCs are heating up. OnCusp Therapeutics now needs capital discipline to turn CUSP06 promise into clinical and investor credibility.
Why Kelun-Biotech’s sac-TMT review could reshape China’s lung cancer ADC market
ADC ambition meets Keytruda dominance. Kelun-Biotech’s sac-TMT filing could test how far TROP2 combinations can move in lung cancer.
ASCO 2026: Tubulis set to present maturing Phase I/IIa data on TUB-040 exatecan ADC in PROC
Tubulis presents updated TUB-040 Phase I/IIa data at ASCO 2026. Here is what the NAPISTAR 1-01 readout means for NaPi2b and ovarian cancer treatment.
AACR 2026: Can Zai Lab’s zocilurtatug pelitecan change the treatment picture for small cell lung cancer brain metastases?
Read how Zai Lab’s zocilurtatug pelitecan posted strong AACR 2026 data in SCLC brain metastases and NECs, and what it could change next.
Why DualityBio’s China filing for trastuzumab pamirtecan matters in the HER2 breast cancer ADC race
DualityBio’s trastuzumab pamirtecan has entered China review for HER2-positive breast cancer. Read what this filing could change next.
What the NEOK002 IND milestone changes for Biocytogen, NEOK Bio, and ADC competition
NEOK002 has cleared the FDA IND stage. Read why this bispecific ADC matters for solid tumors, clinical strategy, and the next phase of ADC competition.
How Orum Therapeutics plans to solve GSPT1 toxicity with a DAC approach in AML
Orum Therapeutics presents ORM-1153 DAC preclinical data at AACR 2026, including primate safety findings ahead of a planned AML IND filing. Read the analysis.
Can Mabwell’s ADC 7MW4911 overcome drug resistance in late-stage GI cancers?
Mabwell begins U.S. trial of novel CDH17-targeting ADC 7MW4911 for resistant GI cancers. Learn what makes this payload and target combination clinically unique.
Lilly’s sofetabart mipitecan gets FDA Breakthrough Therapy designation for ovarian cancer
Eli Lilly and Company has received Breakthrough Therapy designation from the U.S. Food and Drug Administration for its investigational antibody-drug conjugate, sofetabart mipitecan, also known as LY4170156. The designation applies to adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received prior treatment with bevacizumab and mirvetuximab soravtansine. The novel […]
Is ENHERTU plus pertuzumab on track to redefine first-line treatment in HER2-positive metastatic breast cancer?
EMA begins review of ENHERTU plus pertuzumab for first-line HER2-positive metastatic breast cancer. Find out what this means for frontline therapy options.